Health ❯ Clinical Research

Phase Trials

Phase 2 Trials Phase 1b Drug Efficacy Surrogate Endpoints REMAIN Study Patient Outcomes

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

The early Phase 2 readout supports a move to Phase 3 in Q3 2026.

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears